apomorphine has been researched along with Basal Ganglia Diseases in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (46.67) | 18.7374 |
| 1990's | 10 (33.33) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A | 1 |
| Antonutti, L; Capus, L; Ferigo, L; Pizzolato, G; Simonetto, M; Zanet, L; Zorzon, M | 1 |
| Andersen, MB; Fuxe, K; Gerlach, J; Werge, T | 1 |
| Ablordeppey, SY; Li, S; Lyles-Eggleston, M; Sikazwe, DM | 1 |
| Hidaka, M; Kim, DS; Oi, S | 1 |
| Allen, RM | 1 |
| Hosokawa, S; Kato, M; Kuroiwa, Y; Shima, F; Tobimatsu, S | 1 |
| Chateau, R; Gaio, JM; Hommel, M; Pellat, J; Perret, J; Pollak, P | 1 |
| Christoffersen, CL; Corbin, AE; Heffner, TG; Meltzer, LT; Ninteman, FW; Serpa, KA; Wiley, JN; Wise, LD | 1 |
| Malick, JB; Migler, BM; Warawa, EJ | 1 |
| Cooper, T; Howard, A; Kane, JM; Kronig, MH; Lieberman, JA; Masiar, SJ; Novacenko, H; Pollack, S; Safferman, AZ; Szymanski, S | 1 |
| Böck, JC; Cordes, M; David, I; Hierholzer, J; Horowski, R; Poewe, W; Sander, B; Schelosky, L | 1 |
| Castelli, L; Cordes, M; Felix, R; Hierholzer, J; Poewe, W; Schelosky, L | 1 |
| Dixon, AK; Gull, P; Hoyer, D; Jaton, AL; Markstein, R; McAllister, K; Rüdeberg, C; Urwyler, S | 1 |
| Bassi, A; Cicardi, MC; Loberti, M; Pierantozzi, M; Semprini, R; Stanzione, P; Traversa, R | 1 |
| Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K | 1 |
| Christoffersen, CL; Meltzer, LT | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Giacomini, P; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Fowler, PJ; Kaiser, C; Macko, E; Sarau, H; Tedeschi, DH; Zirkle, CL | 1 |
| Crossman, AR; Gergies, SW; Sambrook, MA; Slater, P | 1 |
| Wolfarth, S | 1 |
| Marsden, CD; Pycock, C; Tarsy, D | 1 |
| Christofferson, CL; Corbin, A; Demattos, S; DeWald, HA; Meltzer, LT; Myers, SL; Pugsley, TA; Shih, YH; Whetzel, SZ; Wiley, JN | 1 |
| Fernandez Pardal, MM; Micheli, F | 1 |
| Chase, TN | 1 |
| Anagnoste, B; Battista, AF; Fuxe, K; Goldstein, M; Miyamoto, T | 1 |
| Calne, DB; Reid, JL | 1 |
| Hornykiewicz, O | 1 |
| Arnold, OH; Collard, J; Deniker, P; Ginestet, D; Hippius, H; Itil, TM; Labhardt, F; Leeds, AA; Montanini, R; Morozov, G; Simon, P; Villeneuve, A | 1 |
| Julou, L | 1 |
5 review(s) available for apomorphine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology.
Topics: Amantadine; Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Binding, Competitive; Butaclamol; Humans; Kinetics; Spiperone | 1983 |
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Movement Disorders; Parasympathetic Nervous System; Parasympathomimetics; Parkinson Disease; Parkinson Disease, Secondary; Rabbits; Rats; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra; Synapses | 1976 |
Drug-induced extrapyramidal disorders.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Benztropine; Dihydroxyphenylalanine; Dopamine; Drug-Related Side Effects and Adverse Reactions; Extrapyramidal Tracts; Haloperidol; Humans; Methyltyrosines; Movement Disorders; Phenothiazines; Phenylacetates; Probenecid; Reserpine; Synaptic Transmission; Tetrabenazine; Tranquilizing Agents; Trihexyphenidyl | 1972 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Histamine H1 Antagonists; Humans; Mental Disorders; Methyldopa; Movement Disorders; Norepinephrine; Parasympatholytics; Serotonin; Synaptic Transmission | 1972 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Electric Stimulation; Extrapyramidal Tracts; Humans; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Phenylacetates; Reserpine; Substantia Nigra; Visual Cortex | 1972 |
3 trial(s) available for apomorphine and Basal Ganglia Diseases
| Article | Year |
|---|---|
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1998 |
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation.
Topics: Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Dyskinesias; Electric Stimulation Therapy; Female; Functional Laterality; Globus Pallidus; Humans; Male; Middle Aged; Parkinson Disease | 2001 |
Responses to lisuride in Meige's disease and chorea.
Topics: Aged; Apomorphine; Basal Ganglia Diseases; Clinical Trials as Topic; Ergolines; Female; Humans; Huntington Disease; Lisuride; Male; Meige Syndrome; Middle Aged | 1986 |
22 other study(ies) available for apomorphine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines | 2015 |
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Disease Progression; Dopamine Agonists; Drug Resistance; Fever; Humans; Male; Ondansetron; Parkinson Disease; Respiratory Insufficiency; Serotonin Antagonists; Syndrome; Treatment Outcome | 2008 |
The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Topics: Adenosine; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Arousal; Basal Ganglia Diseases; Behavior, Animal; Cebus; Conscious Sedation; Dopamine Agonists; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Motor Activity; Phenethylamines; Purinergic P1 Receptor Agonists; Receptor, Adenosine A2A; Stereotyped Behavior | 2002 |
The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+.
Topics: Acetyl-CoA Carboxylase; Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Carrier Proteins; Catalepsy; Dopamine Agonists; Fatty Acid Synthase, Type II; Haloperidol; Humans; Male; Mice; Psychomotor Performance; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior | 2003 |
"Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Hydrocephalus; Kaolin; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Time Factors | 2004 |
Local cerebral glucose utilization altered in rats with unilateral electrolytic striatal lesions and modification by apomorphine.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Brain; Brain Mapping; Corpus Striatum; Glucose; Male; Motor Activity; Posture; Rats; Rats, Inbred Strains | 1984 |
[Modification of extrapyramidal signs by apomorphine associated with various dopaminergic antagonists].
Topics: Aged; Apomorphine; Basal Ganglia Diseases; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Movement Disorders; Receptors, Dopamine | 1982 |
CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Apomorphine; Autoreceptors; Avoidance Learning; Basal Ganglia Diseases; Dopamine Agonists; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Saimiri | 1995 |
Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Cats; Cebus; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Fixation, Ocular; Male; Mice; Motor Activity; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Saimiri; Stereotyped Behavior; Swimming | 1993 |
Predictors of response to clozapine.
Topics: Adult; Age Factors; Age of Onset; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Clozapine; Female; Growth Hormone; Humans; Male; Probability; Prolactin; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 1994 |
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
[Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Brain; Contrast Media; Dopamine Agonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1996 |
SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Apomorphine; Basal Ganglia Diseases; Catalepsy; Cattle; Dopamine Antagonists; Humans; In Vitro Techniques; Limbic System; Male; Mice; Motor Activity; Prolactin; Quinoxalines; Radioligand Assay; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptors, Dopamine D1; Retina; Sympathectomy, Chemical | 1996 |
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Case-Control Studies; Dopamine Agonists; Evoked Potentials, Somatosensory; Humans; Levodopa; Median Nerve; Middle Aged; Parkinson Disease; Psychotic Disorders; Reaction Time; Reference Values | 1995 |
Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Cebus; Female; Haloperidol; Male; Serotonin Receptor Agonists; Stereoisomerism; Time Factors | 1998 |
Pharmacological evaluation of clomacran, a new potent psychotropic agent.
Topics: Acridines; Adenylyl Cyclase Inhibitors; Animals; Antipsychotic Agents; Apomorphine; Autonomic Nervous System; Basal Ganglia Diseases; Behavior, Animal; Chlorpromazine; Chlorprothixene; Conditioning, Psychological; Corpus Striatum; Dogs; Dopamine; Female; Haplorhini; Hemodynamics; Humans; Lethal Dose 50; Macaca mulatta; Male; Mice; Motor Activity; Rage; Rats; Reaction Time; Stereotyped Behavior; Trifluoperazine | 1977 |
The neurological basis of motor asymmetry following unilateral 6-hydroxydopamine brain lesions in the rat: the effect of motor decortication.
Topics: Amphetamine; Animals; Apomorphine; Basal Ganglia; Basal Ganglia Diseases; Brain Mapping; Cerebral Decortication; Female; Globus Pallidus; Hydroxydopamines; Motor Cortex; Neural Pathways; Rats; Thalamic Nuclei | 1977 |
Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior; Biogenic Amines; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Chlorpromazine; Clozapine; Corpus Striatum; Dextroamphetamine; Diazepam; Dopamine; Haloperidol; Humans; Hydroxydopamines; Levodopa; Male; Metoclopramide; Mice; Motor Activity; Pentobarbital; Phenoxybenzamine; Pimozide; Promethazine; Stereotyped Behavior; Tranquilizing Agents | 1975 |
Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Cebus; Corticosterone; Coumarins; Dopamine Agents; Guanylyl Imidodiphosphate; Male; Mice; Motor Activity; Piperazines; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Saimiri | 1992 |
Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Bucladesine; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Depression, Chemical; Dopamine; Drug Therapy, Combination; Haloperidol; Haplorhini; Levodopa; Receptors, Drug; Stimulation, Chemical; Tremor | 1974 |
Definition and classification of neuroleptics.
Topics: Amphetamine; Animals; Apomorphine; Autonomic Nervous System; Basal Ganglia Diseases; Behavior; Catalepsy; Chemical Phenomena; Chemistry; Humans; Hypnotics and Sedatives; Motor Activity; Parkinson Disease, Secondary; Psychotic Disorders; Structure-Activity Relationship; Tranquilizing Agents | 1970 |
On the interaction between neuroleptics and antiparkinson drugs.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Dogs; Drug Interactions; Humans; Rats; Reserpine; Tranquilizing Agents | 1970 |